While Arcutis Biotherapeutics Inc has underperformed by -1.76%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT fell by -33.53%, with highs and lows ranging from $15.21 to $1.76, whereas the simple moving average jumped by 37.18% in the last 200 days.
On January 03, 2024, Mizuho Upgraded Arcutis Biotherapeutics Inc (NASDAQ: ARQT) to Buy. A report published by Mizuho on October 26, 2023, Downgraded its rating to ‘Neutral’ for ARQT. Goldman also Downgraded ARQT shares as ‘Neutral’, setting a target price of $6 on the company’s shares in a report dated October 13, 2023. Needham Initiated an Buy rating on September 07, 2022, and assigned a price target of $46. Goldman initiated its ‘Buy’ rating for ARQT, as published in its report on March 17, 2022. Mizuho’s report from June 30, 2021 suggests a price prediction of $58 for ARQT shares, giving the stock a ‘Buy’ rating. Morgan Stanley also rated the stock as ‘Overweight’.
Analysis of Arcutis Biotherapeutics Inc (ARQT)
Further, the quarter-over-quarter increase in sales is 1765.66%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Arcutis Biotherapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 6.80, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 4.66M can be a very valuable indicator of volatility for ARQT stock. On a monthly basis, the volatility of the stock is set at 8.57%, whereas on a weekly basis, it is put at 7.88%, with a loss of -11.40% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.00, showing growth from the present price of $8.94, which can serve as yet another indication of whether ARQT is worth investing in or should be passed over.
How Do You Analyze Arcutis Biotherapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.40%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 84.39% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARQT shares are owned by institutional investors to the tune of 84.39% at present.
